Hemostemix Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HMTXF research report →
Price Chart
About the company
Hemostemix Inc. , a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function.
- CEO
- Thomas A. Smeenk
- IPO
- 2016
- Employees
- 488
- HQ
- Calgary, AB, CA
Get TickerSpark's AI analysis on HMTXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.64M
- P/E
- -1.42
- PEG
- -0.02
- P/S
- 0.00
- P/B
- -1.24
- EV/EBITDA
- -2.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 92.37%
- ROIC
- 338.03%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-45.96+33.9%
- Op Income
- $-5,628,274
- Net Income
- $-4,710,088.7-80.0%
- EPS
- $-0.03-4.7%
- OCF Growth
- -138.2%
- FCF Growth
- -138.2%
- 52W High
- $0.08
- 52W Low
- $0.02
- 50D MA
- $0.04
- 200D MA
- $0.05
- Beta
- 0.61
- RSI (14)
- 18
- Avg Volume
- 7.28K
No earnings-call transcripts are available for HMTXF yet.
- Free Float
- 79.6%
- Shares Outstanding
- 211.44M
- Float Shares
- 168.41M
Our HMTXF coverage
Recent articles, reports, and earnings notes.
No research on HMTXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HMTXF report →Hemostemix to Highlight Commercial Phase I Longevity Treatment at Small Cap Growth Investor Conference
newsfilecorp.com · Nov 19
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
newsfilecorp.com · Oct 7
Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit
newsfilecorp.com · Sep 28
Hemostemix Non Brokered Private Placement
newsfilecorp.com · Sep 23
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
newsfilecorp.com · Aug 20
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
newsfilecorp.com · Aug 12
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
newsfilecorp.com · Jul 30
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
newsfilecorp.com · Jul 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.